Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia

Leukemia and Lymphoma

Volumn 44, Issue 9, 2003, Pages 1457-1462

  Linn, Y C ^a   Hui, Kam M ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

CD+CD56+; CTL; Cytokine induced killer cells; Graft vs leukemia; Leukemia; Natural killer cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; CELL RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; BONE MARROW CELL; CANCER SURVIVAL; CELL ACTIVITY; CELL INTERACTION; CELL KILLING; CELL MATURATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DONOR; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SCID MOUSE; SPLEEN CELL; TARGET CELL;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD56; CELLS, CULTURED; CLINICAL TRIALS, PHASE I; CYTOTOXICITY, IMMUNOLOGIC; FORECASTING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS; LEUKEMIA; LYMPHOMA; MICE; MICE, SCID; T-LYMPHOCYTE SUBSETS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038235904     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000083082     Document Type: Review

References (37)

1. Lafreniere, R. and Rosenberg, S.A. (1985) "Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2", Cancer Research 45, 3735-3741.
2. Lafreniere, R. and Rosenberg, S.A. (1985) "Adoptive immunotherapy of murine hepatic metastasis with lymphokine activated kill (LAK) cells and recombinant interleukin 2 (IL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and adenocarcinoma", Journal of Immunology 135, 4273-4280.
3. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Schiloni, E., Vetto, J.T., Seipp, C.A., Simpson, C. and Reichert, C.M. (1985) "Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleuin-2 to patients with metastatic cancer", New England Journal of Medicine 313, 1485-1493.
4. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.R., Leitman, S., Linehan, W.M., Robertson, C.N., Lee, R.E., Rubin, R.T., Seipp, C.A., Simpson, C.G. and White, D.E. (1997) "A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone", New England Journal of Medicine 316, 889-897.
5. Rosenberg, S.A., Yang, J.C., White, D.E. and Steinberg, S.M. (1998) "Durability of complete responses in patients with metastatic carcinoma treated with high dose interleukin-2", Annals of Surgery 228, 307-319.
6. Rosenberg, S.A., Packard, B.S., Aebersold, D.M., Solomon, D., Topalian, S.L., Simon, P., Lotze, M.T., Yang, J.C. and Seipp, C.A. (1988) "Use of tumour-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma (special report ", New England Journal of Medicine 319, 1676-1680.
7. Rosenberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. and White, D.E. (1994) "Treatment of patients with metastatic melanoma with autologous TIL and IL-2", Journal of National Cancer Institute 86, 1159-1166.
8. Benyunes, M.C., Massumoto, C., York, A., Higuchi, C.M., Buckner, C.D., Thompson, J.A., Petersen, F.B. and Fefer, A. (1993) "IL-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplant for acute myelogenous leukemia", Bone Marrow Transplantation 12, 159-163.
9. Lanier, L.L., Le, A.M., Civin, C.I., Loken, M.R. and Phillips, J.H. (1986) "The relationship of CD16 (Leu-11) and Lcu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes", Journal of Immunology 136, 4480-4486.
10. Schmidt, R.E., Murray, C., Daley, J.F., Schlossman, S.F. and Ritz, J. (1986) "A subset of natural killer cells in peripheral blood displays a mature T cell phenotype", Journal of Experimental Medicine 164, 351-356.
11. Schmidt-Wolf, I.G.H., Negrin, R.S., Kiem, H.P., Blume, K.G. and Weissman, I.L. (1991) "Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumour cell activity", Journal of Experimental Medicine 174, 139-149.
12. Schmidt-Wolf, I.G.H., Lefterova, P., Mehta, B.A., Fernandez, L.P., Huhn, D., Blume, K.G., Weissman, I.L. and Negrin, R.S. (1993) "Phenotypic characterization and identification of effector cells involved in tumour cell recognition of cytokine-induced killer cells", Experimental Haematology 21, 1673-1679.
13. Schmidt-Wolf, I.G., Lefterova, P., Johnston, V., Scheffold, C., Csipai, M., Mehta, B.A., Tsuruo, T., Huhn, D. and Negrin, R.S. (1996) "Sensitivity of multidrug-resistant tumour cell lines to immunologic efector cells", Cellular Immunology 169, 85-90.
14. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency", Journal of Immunology 153, 1687-1696.
15. Scheffold, C., Brandt, K., Johnston, V., Lefterova, P., Degen, B., Schontube, M., Huhn, D., Neubauer, V. and Schmidt-Wolf, I.G.H. (1995) "Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia", Bone Marrow Transplantation 15, 33-39.
16. + cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice", Blood 92(9), 3318-3327.
17. +cells from peripheral blood progenitor cells of patients undergoing autologous haemopoietic cell transplant", Biology of Blood and Marrow Transplantation 7, 216-222.
18. Linn, Y.C., Lau, L.C. and Kam Hui, M. (2002) "Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts", British Journal of Haematology 116, 78-86.
19. Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G. and Trinchieri, G. (2002) "Reciprocal activating interaction between natural killer cells and dendritic cells", Journal of Experimental Medicine 193, 327-333.
20. Marten, A., Ziske, C., Schottker, B., Renoth, S., Weineck, S., Buttgereit, P., Schakowski, F., von Rucker, A., Sauerbruch, T. and Schmidt-Wolf, I.G.H. (2001) "Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations", Journal of Immunotherapy 24(6), 502-510.
21. Ziske, C., Marten, A., Schottker, B., Buttgereit, P., Schakowski, F., Gorschluter, M., von Rucker, A., Scheffold, C., Chao, N., Sauerbruch, T. and Schmidt-Wolf, I.G.H. (2001) "Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9", Molecular Therapy. 3(1), 54-60.
22. Marten, A., Renoth, S., von Lilienfeld-Total, M., Buttgereit, P., Schakowski, F., Glasmacher, A., Sauerbruch, T. and Schmidt-Wolf, I.G.H. (2001) "Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells", Haematologica 86, 1029-1037.
23. + natural killer T cells with limited capacity for graft vs. host disease induction due to interferon-γ production", Blood 97, 2923-2931.
24. + NK-T cells in the treatment of lymphoma", Biology of Blood and Marrow Transplantation 7, 532-542.
25. Leemhuis, T., Wells, S., Hom, P., Scheffold, C., Edinger, M. and Negrin, R.S. (2000) "Autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma", Blood Abstract(2000), #3624.
26. Schmidt-Wolf, I.G.H., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., Heuft, H.G., Prange, G., Korte, M., Takeya, M., Dorbic, T., Neubauer, A., Wittig, B. and Huhn, D. (1999) "Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma", British Journal of Cancer 81(16), 1009-1016.
27. Farag, S.S., Fehniger, T.A., Ruggeri, L., Verladi, A. and Caligiuri, M.A. (2002) "Natural killer cell receptors: new biology and insights into the graft-vs. leukemia effect", Blood 100, 1935-1947.
28. + T cells", Current Opinion in Immunology 13, 465-470.
29. Moser, J.M., Byers, A.M. and Lukacher, A.E. (2002) "NK cell receptor in antiviral immunity", Current Opinion in Immunology 14, 509-516.
30. Scheffold, C., Chu, Y., Kornacker, M., Verneris, M. and Negrin, R.S. (1998) "HLA class-I specific inhibitory receptors in human cytolytic effector cells", Blood Abstract, #2240.
31. Guerra, N., Guillard, M., Angevin, E., Echcharkir, H., Escudier, B., Moretta, A., Chouaib, S. and Caignard, A. (2000) "Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas", Blood 95(9), 2883-2889.
32. Falk, C.S., Noessner, E., Weiss, E.H. and Schendel, D.J. (2002) "Retaliation against tumor cells showing aberrant HLA expression using Lymphokine Activated-derived T cells", Cancer Research 62, 480-487.
33. Lowdell, M.W., Craston, R., Samuel, D., Wood, M.E., O'neill, E., Saha, V. and Grant Prentice, H. (2002) "Evidence that continued remission in patients treated for acute leukemia is dependent upon autologous natural killer cells", British Journal of Haematology 117, 821-827.
34. Collins, R.H., Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoski, N., Chetrit, A., Antin, J.H. and Nemunaitis, J. (1997) "Donor leukocyte infusion in 140 patients with relapsed malignancy after allogeneic bone marrow transplant", Journal of Clinical Oncology 15, 433-444.
35. for the European Group for Blood and Marrow Transplantation Working PartyKolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, E. and Ansari, H. (1995) "Graft vs. leukemia effect of donor lymphocyte transfusion in marrow grafted patients", Blood 86, 2041-2050.
36. Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R.S., Martelli, M.F. and Velardi, A. (1999) "Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation", Blood 94(1), 333-339.
37. Ruggeri, L., Capanni, M., Urbani, E., Aversa, F., Martelli, M. and Verladi, A. (2000) "KIR epitope incompatibility in the GvH direction predicts control of leukemia relapse after mismatched hematopoietic transplantation", Blood Abstract 96, 479a.